is an IP litigation partner with a specialist focus and expertise in high-stakes life science patent litigation, particularly in the pharmaceutical industry, diagnostics and the emerging fields of precision medicine and cell and gene therapy. His previous case experience covers a broad range of technical fields, including oncology, molecular diagnostics and biostatistics, and has often involved litigating issues at the cutting edge of the development of the law, notably in relation to the enforcement and validity of second medical-use patents. Daniel is a prolific writer and speaker on life science and IP topics and is particularly regarded as a thought leader on the subject of CRISPR gene editing. He is active as a member of AIPPI and EPLAW and formerly served as Associate to Justice Yates of the Federal Court of Australia.
Chambers and Partners make no representation or endorsement of the quality and services supplied
by companies or firms that may be found on this website. In no event will Chambers and Partners
be liable for any damages including, without limitation, indirect or consequential damages,
or any damages whatsoever arising from use or loss of use, data, or profits, whether in action
of contract, negligence or other tort action, arising out of or in connection with the use
of the website.